Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Astellas Pharma Inc. is a global pharmaceutical company based in Japan, specializing in innovative therapies in areas such as urology, oncology, and immunology. Its competitive position is strengthened by a robust pipeline of drugs, including the prostate cancer treatment Xtandi, and a focus on research and development across key markets in North America and Europe.
Astellas generates revenue primarily through the sale of patented pharmaceuticals, leveraging its strong R&D capabilities to develop innovative treatments. The company's pricing power is supported by the high demand for its specialized drugs, particularly in oncology and urology, where competition is limited. Astellas also benefits from a diversified global presence, reducing reliance on any single market.
Approval and launch of new drugs, particularly in oncology and urology
Regulatory changes affecting drug pricing and reimbursement
Partnerships or collaborations with other pharmaceutical companies
Market expansion in emerging markets such as China and India
Regulatory changes that could impact drug pricing and market access
Technological disruption in drug development processes
Emergence of generic competitors for key products
Increased competition from biotech firms in oncology
Potential for rising R&D costs impacting profitability
Currency fluctuations affecting international revenue
moderate - Astellas' performance is somewhat linked to the economic cycle, as healthcare spending can fluctuate with consumer confidence and GDP growth.
Interest rates affect Astellas primarily through the cost of capital for R&D investments. Higher rates could increase financing costs, potentially impacting future growth initiatives.
minimal - Astellas maintains a conservative debt profile with a debt/equity ratio of 0.31, reducing reliance on credit markets.
growth - Astellas' strong pipeline and revenue growth attract growth-focused investors.
moderate - The stock has shown historical volatility consistent with biotech/pharma sectors, influenced by clinical trial results and regulatory news.
